ORGO
Organogenesis Holdings Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$1.02
+2.03%Year over year
Reported trailing growth
- Revenue
- +6.3%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +144.9%
- Operating cash flow
- +196.4%
Forward estimates
Based on analyst estimates
- Revenue
- -49.8%
- EBITDA
- —
- EPS
- +59.1%
Three-year CAGR
- Revenue
- +7.7%
- EBITDA
- +22.4%
- EBIT
- +35.8%
- Net income
- +33.6%
- EPS
- +10.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026